Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding

Figures

• 

  Figure 1.. Patient Selection Criteria The study population selected patients with nonvalvular atrial fibrillation (AF) with high risk for gastrointestinal bleed who initiated an oral anticoagulant (OAC) of interest, resulting in 6 PSM cohorts ranging from 22 282 to 76 500 matched patients. CKD indicates chronic kidney disease; HAS-BLED, hypertension, kidney or liver disease, stroke history, prior bleeding, unstable international normalized ratio, age 65 years or older, drug or alcohol use; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; GI, gastrointestinal; and VTE, venous thromboembolism.

• 

  Figure 2.. Propensity Score–Matched Incidence Rates and Hazard Ratios of Stroke and/or Systemic Embolism (SE) and Major Bleeding for Non–Vitamin K Antagonist Oral Anticoagulant (NOAC) vs Warfarin Cox proportional hazard models with robust sandwich estimates were used to evaluate the risk of stroke and/or SE and major bleeding. GI indicates gastrointestinal; ICH, intracranial hemorrhage.

• 

  Figure 3.. Propensity Score–Matched Incidence Rates and Hazard Ratios of Stroke and/or Systemic Embolism (SE) and Major Bleeding for Non–Vitamin K Antagonist Oral Anticoagulant (NOAC) Comparisons Cox proportional hazard models with robust sandwich estimates were used to evaluate the risk of stroke and/or SE and major bleeding. GI indicates gastrointestinal; ICH, intracranial hemorrhage.